These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 15449632)

  • 1. The economic impact of payer policies after the Rx-to-OTC switch of second-generation antihistamines.
    Sullivan PW; Nichol MB
    Value Health; 2004; 7(4):402-12. PubMed ID: 15449632
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Transitioning the second-generation antihistamines to over-the-counter status: a cost-effectiveness analysis.
    Sullivan PW; Follin SL; Nichol MB
    Med Care; 2003 Dec; 41(12):1382-95. PubMed ID: 14668671
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The effect of the Rx-to-OTC switch of loratadine and changes in prescription drug benefits on utilization and cost of therapy.
    Sullivan PW; Nair KV; Patel BV
    Am J Manag Care; 2005 Jun; 11(6):374-82. PubMed ID: 15974556
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of product switching after a state Medicaid program began covering loratadine OTC 1 year after market availability.
    Trygstad TK; Hansen RA; Wegner SE
    J Manag Care Pharm; 2006 Mar; 12(2):108-20. PubMed ID: 16515369
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost and utilization impacts of oral antihistamines in the California Medi-Cal program.
    Hay JW; Leahy M
    Value Health; 2005; 8(4):506-16. PubMed ID: 16091028
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost-benefit analysis of first-generation antihistamines in the treatment of allergic rhinitis.
    Sullivan PW; Follin SL; Nichol MB
    Pharmacoeconomics; 2004; 22(14):929-42. PubMed ID: 15362929
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The cost-effectiveness of treatment with desloratadine in patients with persistent allergic rhinitis.
    Sullivan PW; Navaratnam P; Lorber R; Shekar T
    Curr Med Res Opin; 2010 Jun; 26(6):1389-97. PubMed ID: 20384438
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The effect on social welfare of a switch of second-generation antihistamines from prescription to over-the-counter status: a microeconomic analysis.
    Shih YC; Prasad M; Luce BR
    Clin Ther; 2002 Apr; 24(4):701-16. PubMed ID: 12017413
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Costs of second-generation antihistamines in the treatment of allergic rhinitis: US perspective.
    Hay JW; Kaliner MA
    Curr Med Res Opin; 2009 Jun; 25(6):1421-31. PubMed ID: 19422280
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects on the cost and utilization of proton pump inhibitors from adding over-the counter omeprazole to drug benefit coverage in a state employee health plan.
    Harris BN; West DS; Johnson J; Hong SH; Stowe CD
    J Manag Care Pharm; 2004; 10(5):449-55. PubMed ID: 15369428
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Switching prescription drugs to over the counter: consumers may benefit financially in examples from the US.
    Sullivan PW
    BMJ; 2005 Apr; 330(7496):904-5. PubMed ID: 15831881
    [No Abstract]   [Full Text] [Related]  

  • 12. Optimizing quality of care and cost effectiveness in treating allergic rhinitis in a managed care setting.
    Nash DB; Sullivan SD; Mackowiak J
    Am J Manag Care; 2000 Jan; 6(1 Suppl):S3-15; quiz S19-20. PubMed ID: 11009751
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Policy analysis of the conversion of histamine2 antagonists to over-the-counter use.
    Kalish SC; Bohn RL; Avorn J
    Med Care; 1997 Jan; 35(1):32-48. PubMed ID: 8998201
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Coupon programs curb antihistamine utilization.
    Berberabe T
    Manag Care; 2003 Aug; 12(8):28-9. PubMed ID: 12966848
    [No Abstract]   [Full Text] [Related]  

  • 15. Assessing satisfaction with desloratadine and fexofenadine in allergy patients who report dissatisfaction with loratadine.
    Glass DJ; Harper AS
    BMC Fam Pract; 2003 Aug; 4():10. PubMed ID: 12917016
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Managed care market perspectives on the over-the-counter availability of statins.
    Richards MK; Blumenfield S; Lyon RA
    J Manag Care Pharm; 2004; 10(6):543-50. PubMed ID: 15548127
    [TBL] [Abstract][Full Text] [Related]  

  • 17. South Dakota Medicaid will now cover OTC Loratadine and OTC Prilosec.
    Brandenburg V; Darger D; Christianson H; Goeden G; Engelbrecht J; Hedge D; Holm R; Ladwig W;
    S D J Med; 2005 Jan; 58(1):17. PubMed ID: 15696732
    [No Abstract]   [Full Text] [Related]  

  • 18. A 30-month evaluation of the effects on the cost and utilization of proton pump inhibitors from adding omeprazole OTC to drug benefit coverage in a state employee health plan.
    West DS; Johnson JT; Hong SH
    J Manag Care Pharm; 2006; 12(1):25-32. PubMed ID: 16420105
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Access to allergy care: implications for quality healthcare and public safety.
    Berger WE; Rosenwasser L; Atwater JS
    Manag Care Q; 2003; 11(2):8-11. PubMed ID: 12968437
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Assessing the economic impact of Rx-to-OTC switches: systematic review and guidelines for future development.
    Cohen J; Millier A; Karray S; Toumi M
    J Med Econ; 2013; 16(6):835-44. PubMed ID: 23597040
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.